Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data in Patients with Relapsed/Refractory CLL, Including Those with High-Risk Disease, Previously Treated with Ibrutinib, at ASH 2018

Eighty one percent overall response rate and 43% complete response rate observed in heavily pre-treated patients. Majority of patients evaluable for minimal residual disease achieved early, undetectable MRD.